Drugs / Daratumumab and Hyaluronidase-fihj
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05807048 | Jun 2023 → Nov 2025 | lung cancer | NYU Langone Health | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daratumumab and Hyaluronidase-fihj | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05807048 ↗ |
| Route | Subcutaneous | “injection for subcutaneous use” NCT05807048 ↗ |